Berberine ursodeoxycholate

• CAS Number:

  1868138-66-2

• UNSPSC Description:

  Berberine ursodeoxycholate (HTD1801), an ionic salt of Berberine and Ursodeoxycholic acid, is an orally active and potent hypolipidemic agent. Berberine ursodeoxycholate shows significantly great reduction in liver fat content. Berberine ursodeoxycholate has a broad spectrum of metabolic activity. Berberine ursodeoxycholate can be used for the research of hyperlipidemia, non-alcoholic steatohepatitis (NASH) and diabetes[1][2].

• Target Antigen:

  Others

• Type:

  Reference compound

• Related Pathways:

  Others

• Applications:

  Metabolism-sugar/lipid metabolism

• Field of Research:

  Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/berberine-ursodeoxycholate.html

• Solubility:

  DMSO : 5 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  COC1=C2C=[N+]3C(C4=CC(OCO5)=C5C=C4CC3)=CC2=CC=C1OC.C[C@@]67[C@](CC[C@]7([H])[C@H](C)CCC([O-])=O)([H])[C@@]8([H])[C@@](CC6)([H])[C@@]9([C@](C[C@@H](CC9)O)([H])C[C@@H]8O)C

• Molecular Weight:

  727.93

• References & Citations:

  [1]Harrison SA, et al. A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes. Nat Commun. 2021 Sep 17;12(1):5503.|[2]Di Bisceglie AM, et al. Pharmacokinetics and pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with hyperlipidemia. Lipids Health Dis. 2020 Nov 12;19(1):239.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  Phase 3